Molecular targeting meets surgical imaging.

Amyno is developing fluorescent imaging agents that create selective contrast between anatomical structures and surrounding tissue. We are at the research stage: proof-of-concept is complete, and we are now developing and validating targeted agents.

Contrast guided by molecular identity.

Conventional fluorescence mostly shows where dye or fluid travels, such as perfusion or lymphatic drainage, not what a structure is. We pair a near-infrared fluorescent reporter with a molecule selected to bind a specific structure, so the signal is designed to reflect the structure itself.

In plain terms: a targeting molecule that recognizes a structure, carrying a near-infrared dye that can be seen with the right light and camera.

First application: lymphatic vessels.

Lymphatic vessels are difficult to distinguish from surrounding fat and connective tissue, and damage to them can cause lymphedema, a chronic condition marked by swelling, infection risk, and high medical costs. Roughly 20–30% of patients develop it following axillary lymph node dissection.1

Our first agent targets lymphatic vessels in axillary breast cancer surgery, and our near-term laboratory work tests its binding, fluorescence, and specificity against appropriate controls.

1. Woodfin AA, Caudle AS. Surg Oncol Clin N Am 2023;32(4):693–703.

Designing for practical translation.

Our agents are meant to work with established near-infrared imaging systems, with compatibility assessed system by system. We work with clinicians to identify where added anatomical information matters most.